Substantially all assets of Nobias Therapeutics have been acquired by Synaptiq Therapeutics, a privately held, clinical-stage biotechnology company.  Synaptiq is dedicated to advancing SYN-001 (formerly NB-001) for the treatment of neuropsychiatric symptoms associated with 22q11DS.  

For more information, visit https://www.synaptiqtx.com